A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506. Keywords: cortical blindness and seizures; FK506 neurotoxicity; bone marrow transplantation FK506 (tacrolimus), a fungal metabolite produced by Streptomyces tsukubaenis, is an effective immunosuppressive agent used for bone marrow and organ transplantation patients. A case of FK506 neurotoxicity is discussed.
FK506 (tacrolimus), a fungal metabolite produced by Streptomyces tsukubaenis, is an effective immunosuppressive agent used for bone marrow and organ transplantation patients. A case of FK506 neurotoxicity is discussed.
Case report
A 54-year-old woman had been diagnosed 11 years earlier with extensive low-grade non-Hodgkin's lymphoma. She was treated with chemotherapy and achieved a complete remission. However, 2 years later her disease recurred and she received salvage chemotherapy. One year later, she had high-dose therapy and an autologous peripheral blood stem cell transplant. Her post-transplant course was essentially uneventful until 6 years later when she developed a myelodysplastic syndrome and underwent a matched, unrelated bone marrow transplant (BMT). Cyclophosphamide and total body irradiation were used as conditioning. She had never received intrathecal chemotherapy or brain irradiation prior to this conditioning. Three days prior to her allogenic transplant, cyclosporine was first given as prophylaxis for graft-versus-host disease. During intravenous infusion of this drug she developed chest tightness and wheezing accompanied by acute dyspnea, thready pulse, low oxygen saturation and hypotension. These symptoms reversed with corticosteroid administration. The suspected but unconfirmed allergen was polyoxyethylated castor oil, a vehicle, in addition to alcohol, in the commercial cyclosporine product for injection. Tacrolimus (FK506) was substituted.
Eleven days after the allogenic transplant, she developed acute renal failure following a period of sepsis and hypotension from which she gradually recovered without requiring dialysis. However, on day 22, she developed a slight worsening of her recovering renal function and FK506 toxicity was suspected. On day 23, the blood level of FK506 was 50 ng/ml, exceeding the target level of 10-20 ng/ml, and FK506 dosage was reduced to one attenuated dose on day 28 and then was discontinued. Renal function slowly improved over the next few days but on day 27, when the FK506 level was 20 ng/ml, she complained of confusion and spatial disorientation. Her blood pressure was 156/82 mm Hg. Clinical examination revealed cortical blindness with visual defects and a visual acuity of light perception only. An MRI of the brain, the first that had been performed, demonstrated abnormal signals in the posterior parietal and temporal areas bilaterally ( Figure 1 ). A spinal tap was not performed. Thrombotic thrombocytopenic purpura was considered since occasional schistocytes were seen on the peripheral blood smear. She was platelet transfusion independent after day 19 with a platelet count of 74 000/l on day 30. An elevation in the LDH was noted from day 25 to day 31 which then fell to normal limits. No plasmapheresis was performed. Creatinine levels reached an apex on day 24 and returned to normal by day 28. An EEG performed on day 28 showed frequent right occipital subclinical seizure discharges (Figure 2 ). The patient received prednisone and an intravenous loading dose of fosphenytoin. On day 29 she continued to experience light perception only and was showing denial of blindness, characteristic of the Anton syndrome. A repeat EEG revealed subclinical seizure discharges over both occipital regions, most pronounced on the right. A pattern-shift visual evoked potential (VEP) performed on day 29 showed no reproducible responses following stimulation of the right eye, and a poorly defined response following stimulation of the left eye with a markedly prolonged P100 latency of 198 ms, indicating conduction defects in the visual pathways bilaterally. Bilateral visual pathway conduction defects remained evident on a repeat VEP 4 days later which showed bilateral prolongation of the P100 latency of 191 ms following left eye stimulation and 205 ms following right eye stimulation. Subsequently, her confusion cleared and her vision continued to gradually improve. Within 8 days of the onset of cortical blindness, the corrected visual acuity was 20/30 in the right eye and 20/20 in the left eye. MRI was not repeated. Placing the patient on oral cyclosporine for graftversus-host disease prophylaxis was considered, and although a trial dose resulted in no anaphylaxis, the decision was made to use azathioprine for long-term management. Eight months after transplantation she was receiving low doses of prednisone for mild chronic graft-versushost disease of the skin, had no discernable visual defects and was fully alert and oriented.
Discussion
FK506 is an effective immunosuppressive agent for bone marrow and organ transplantation. 1 It has a similar sideeffect profile to the older and more widely used immunosuppressive agent, cyclosporine. Cyclosporine can produce white matter changes leading to cortical blindness and seizures in different transplant populations including kidney, heart, liver, and bone marrow. [2] [3] [4] [5] [6] [7] There is less known about FK506 neurotoxicity. Cortical blindness and white matter lesions have been previously reported in a liver transplant recipient receiving FK506. 8 The investigators suggested that hepatic encephalopathy may contribute to neurotoxicity via elevated ammonia levels, which increase permeability of the blood-brain barrier, and that the breakdown of the blood-brain barrier may allow for increased passage of lipophilic agents such as FK506 and cyclosporine. The mechanism of neurotoxicity associated with FK506 is not clear, however, and our reported case occurred in a bone marrow transplant recipient with normal liver function. Devine et al 9 described three bone marrow transplant recipients who developed cerebral blindness while receiving FK506. In each case FK506 was discontinued and the visual symptoms reversed within 1-2 weeks of onset.
MRI easily demonstrates the white matter lesions caused by FK506 and cyclosporine toxicity which may not be apparent on CT. Seizures are a well known complication of cyclosporine neurotoxicity and may occur in combination with cortical blindness in patients with FK506 neuro-toxicity. As the seizures may be subclinical, EEG may be necessary for their detection.
When toxicity is suspected, based upon MRI findings and clinical features, discontinuation of the drug should be considered. In our case, FK506 was discontinued, and following a brief course of corticosteroids, azathioprine was substituted without recurrence of neurotoxicity. Azathioprine was chosen instead of cyclosporine because cyclosporine has also been associated with cortical blindness. [2] [3] [4] [5] [6] [7] It is unknown if a reduction in the FK506 dosage would have resulted in a similar outcome. In the three bone marrow transplant recipients reported by Devine and colleagues 9 who developed cortical blindness while receiving FK506, two subsequently received cyclosporine without sequelae. However, it was noted that patients have been described with cerebral blindness secondary to FK506 which recurred after switching to cyclosporine. 10 Azathioprine was subsequently given to our patient as its use has not been associated with cortical blindness.
